On June 12, 2025, CureVac N.V. entered into a purchase agreement with BioNTech SE for a public exchange offer to acquire CureVac's shares, resulting in a major corporate reorganization that will delist CureVac from Nasdaq. This event is significant as it involves a complete acquisition of the company, potentially affecting shareholders' holdings and company operations.